This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
GHRP-2 (5 mg Vial)
GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic hexapeptide that stimulates potent, dose-dependent growth hormone release by activating ghrelin receptors[1].
Quick Reference
What is GHRP-2?
Research overview based on the cited scientific literature.
• Goal: Stimulate endogenous growth hormone secretion through ghrelin receptor activation[1].
• Storage: Lyophilized frozen; reconstituted refrigerated (use within 2–3 weeks for optimal integrity).
Storage Instructions
Proper storage preserves peptide potency.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; powder is stable at room temperature for short periods but freezer storage maximizes shelf life[8].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–3 weeks for optimal integrity[9]. For longer storage, consider aliquoting and freezing at −20 °C (−4 °F) with carrier protein; avoid repeated freeze–thaw cycles.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Always protect from light and heat.
How is GHRP-2 studied?
GHRP-2 is a synthetic growth hormone secretagogue that binds to and activates ghrelin (GH secretagogue) receptors[1]. This activation triggers potent, pulsatile release of growth hormone from the pituitary gland in a dose-dependent manner[4]. Clinical studies in GH-deficient children demonstrated meaningful GH increases even at low doses (0.3–3.0 mcg/kg), with escalating doses over several months showing sustained efficacy[2]. A five-day study in healthy young men reported attenuation of the growth-hormone response and no increase in IGF-I. These findings describe that study's outcomes; they do not establish a routine administration schedule or long-term safety.
What does the research report about GHRP-2?
Observations from clinical and preclinical literature.
• Stimulates robust pulsatile GH release that may support favorable body composition changes and metabolic effects[1][2].
• In combination therapies (e.g., with GHRH analogs), can significantly increase IGF-1 levels when administered with perfect compliance[5][6].
• Reported tolerability must be assessed within each study's population, formulation and follow-up. A favorable short-term finding does not establish long-term safety or justify personal administration.[7]
• Long-term therapy (8–24 months in GH-deficient subjects) has maintained positive effects on growth velocity with careful monitoring[2].
• Occasional mild injection-site reactions (redness, irritation) may occur with subcutaneous administration.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on GHRP-2?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
